Professor Jang Dae-young of Hallim University Sacred Heart Hospital as the new chairman of the Korean Gastrointestinal Cancer Society...Strengthen cooperation in treatment innovation and research
Oct 28, 2025
Jang Dae-young, a professor of hematologic oncology at Hallim University Sacred Heart Hospital, was elected as the 21st president of the Korean Society of Gastric Cancer, the largest association in the Korean stomach cancer field, at the '2025 Korean Society of Gastric Cancer (KINGCA WEEK)' held on September 26.
The Korean Gastric Cancer Society is the largest multidisciplinary academic organization in Korea that has led standardization and research on gastric cancer treatment in Korea since its foundation in 1996. It successfully held the International Society for Gastric Cancer (IGCC) twice in 1999 and 2011 in Korea and has established a position in the world's academic community, and has been hosting the International Academic Conference (KINGCA Week) every year since 2014.
The official academic journal of the Society 'Journal of Gastric Cancer (JGC)' was listed in the SCIE in 2017 and MEDLINE in 2024 and recognized as an international academic journal. Currently, it is leading gastric cancer treatment guidelines and research by focusing on four research groups affiliated with the Korean Association of Laparoscopic Gastrointestinal Tractors (KLASS).
Professor Jang Dae-young is considered a representative authority in the field of gastric cancer in Korea.
It has led clinical research on anticancer treatment and recurrence prevention of a number of gastrointestinal cancers such as gastric cancer, colon cancer, and pancreatic cancer, and has also successfully established live-action evidence (RWE) through a full investigation of gastric cancer and breast cancer patients in Korea. He has also worked hard to develop customized treatments for patients by serving as the chairman of the committee to write clinical guidelines for gastric cancer and participating in the development of standard treatment recommendations for gastric cancer and treatment guidelines.
In addition, he served as the president of the Korea Clinical Trials Center Council, the president of the Korea Cancer Therapy Research Association, the cancer disease review committee member of the Health Insurance Review and Assessment Service, and the chairman of the Korean Cancer Society's health insurance policy committee, contributing to raising Korea's anticancer research capabilities to global levels.
Professor Jang Dae-young said, `The Korean Society of Gastric Cancer has been setting the standards for gastric cancer treatment and research in Korea, and it is an academic organization for gastric cancer that is drawing global attention.' `I will do my best as the chairman to further strengthen patient-centered treatment innovation and research cooperation so that gastric cancer patients can receive better treatment in the future" he expressed his ambition.
The Korean Gastric Cancer Society is the largest multidisciplinary academic organization in Korea that has led standardization and research on gastric cancer treatment in Korea since its foundation in 1996. It successfully held the International Society for Gastric Cancer (IGCC) twice in 1999 and 2011 in Korea and has established a position in the world's academic community, and has been hosting the International Academic Conference (KINGCA Week) every year since 2014.
The official academic journal of the Society 'Journal of Gastric Cancer (JGC)' was listed in the SCIE in 2017 and MEDLINE in 2024 and recognized as an international academic journal. Currently, it is leading gastric cancer treatment guidelines and research by focusing on four research groups affiliated with the Korean Association of Laparoscopic Gastrointestinal Tractors (KLASS).
Professor Jang Dae-young is considered a representative authority in the field of gastric cancer in Korea.
It has led clinical research on anticancer treatment and recurrence prevention of a number of gastrointestinal cancers such as gastric cancer, colon cancer, and pancreatic cancer, and has also successfully established live-action evidence (RWE) through a full investigation of gastric cancer and breast cancer patients in Korea. He has also worked hard to develop customized treatments for patients by serving as the chairman of the committee to write clinical guidelines for gastric cancer and participating in the development of standard treatment recommendations for gastric cancer and treatment guidelines.
In addition, he served as the president of the Korea Clinical Trials Center Council, the president of the Korea Cancer Therapy Research Association, the cancer disease review committee member of the Health Insurance Review and Assessment Service, and the chairman of the Korean Cancer Society's health insurance policy committee, contributing to raising Korea's anticancer research capabilities to global levels.
Professor Jang Dae-young said, `The Korean Society of Gastric Cancer has been setting the standards for gastric cancer treatment and research in Korea, and it is an academic organization for gastric cancer that is drawing global attention.' `I will do my best as the chairman to further strengthen patient-centered treatment innovation and research cooperation so that gastric cancer patients can receive better treatment in the future" he expressed his ambition.
|
This article was translated by Naver AI translator.
